Related Experiment Videos
Screening for fetal chromosomal and subchromosomal disorders
Sarah Harris1, Dallas Reed2, Neeta L Vora3
1University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Seminars in Fetal & Neonatal Medicine
|November 13, 2017
Summary
Prenatal screening for fetal chromosomal disorders has advanced significantly, with cell-free DNA (cfDNA) screening now offering high detection rates for aneuploidies. Understanding cfDNA technology is crucial for obstetricians to provide optimal patient care.
Area of Science:
- Prenatal diagnostics
- Genetics
- Molecular biology
Background:
- Maternal age-related risk assessment was the initial method for aneuploidy screening.
- Screening evolved to include maternal serum analytes and ultrasound markers.
- Maternal plasma cell-free DNA (cfDNA) screening represents a major technological advancement.
Observation:
- Cell-free DNA screening demonstrates high detection rates for common aneuploidies.
- This method also exhibits low false-positive rates.
- Current cfDNA technology enables screening for rarer aneuploidies and subchromosomal abnormalities.
Findings:
- The efficacy of cfDNA screening for fetal chromosomal disorders is well-established.
- The technology's capabilities are expanding to cover a broader spectrum of genetic conditions.
- Ongoing research focuses on optimizing the integration of cfDNA screening into clinical practice.
Implications:
- Obstetric providers must understand the biological basis and limitations of cfDNA screening.
- Accurate and up-to-date information on cfDNA screening is essential for patient counseling.
- Continued evolution of prenatal screening necessitates adaptation in clinical guidelines and practice.